No matches
Rhinology

AFRS Disease Burden Infographic

This infographic highlights the clinical burden of Allergic Fungal Rhinosinusitis (AFRS), including disease severity, recurrence, complications, and impact on patients compared with CRSwNP.

Related resources

Partnering With Patients: Scores That Matter in CRSwNP

Partnering With Patients: Scores That Matter in CRSwNP

interactivity
ERS-ISIAN 2025 | Disease Control in CRSwNP

ERS-ISIAN 2025 | Disease Control in CRSwNP

expert video
ERS-ISIAN 2025 | Type 2 Inflammation: Links with Severe/Uncontrolled CRSwNP

ERS-ISIAN 2025 | Type 2 Inflammation: Links with Severe/Uncontrolled CRSwNP

expert video
ERS-ISIAN 2025 | Type 2 Inflammation and Disease Control in CRSwNP: Current Perspectives and Future Directions

ERS-ISIAN 2025 | Type 2 Inflammation and Disease Control in CRSwNP: Current Perspectives and Future Directions

expert video
ERS-ISIAN 2025 | Treatable Traits in CRSwNP

ERS-ISIAN 2025 | Treatable Traits in CRSwNP

expert video
Compounded Burden of Co-existing Type 2 Airway Diseases

Compounded Burden of Co-existing Type 2 Airway Diseases

expert video
Spotlight on Type 2 Inflammation in the Upper and Lower Airways

Spotlight on Type 2 Inflammation in the Upper and Lower Airways

expert video
CRSwNP Interactive Patient Case Tool

CRSwNP Interactive Patient Case Tool

interactivity
Assessment of Smell Loss in CRSwNP Interactive Infographic

Assessment of Smell Loss in CRSwNP Interactive Infographic

interactivity
CRSwNP Triathlon: An Interactive Learning Experience

CRSwNP Triathlon: An Interactive Learning Experience

interactivity
AANP 2025 | Atopic Diseases & a Case-Based Panel of Nurse Practitioners

AANP 2025 | Atopic Diseases & a Case-Based Panel of Nurse Practitioners

videoanimation
The Burden in Patients with CRSwNP and Coexisting Asthma

The Burden in Patients with CRSwNP and Coexisting Asthma

expert video
Type 2 Inflammation and Sinonasal Barrier Dysfunction in CRSwNP

Type 2 Inflammation and Sinonasal Barrier Dysfunction in CRSwNP

videoanimation
CEORL-HNS 2026 | Emerging Evidence of Biologics for the Treatment Landscape of CRSwNP

CEORL-HNS 2026 | Emerging Evidence of Biologics for the Treatment Landscape of CRSwNP

expert video
Indirect Treatment Comparison of Biologics Approved for CRSwNP

Indirect Treatment Comparison of Biologics Approved for CRSwNP

expert video
Head-to-Head Trials of Biologics in CRSwNP

Head-to-Head Trials of Biologics in CRSwNP

expert video
Type 2 Inflammation: Links With Severe Uncontrolled CRSwNP

Type 2 Inflammation: Links With Severe Uncontrolled CRSwNP

expert video
CRSwNP at Center Stage: Impact of Biologics in Patients with Co-existing Type 2 Asthma

CRSwNP at Center Stage: Impact of Biologics in Patients with Co-existing Type 2 Asthma

expert video
2025 ADVENT Forum | Remodeling in the Airway: A Damaged State of Affairs

2025 ADVENT Forum | Remodeling in the Airway: A Damaged State of Affairs

expert video
2025 ADVENT Forum | Potential for Disease Modification in the Airway

2025 ADVENT Forum | Potential for Disease Modification in the Airway

expert video
Loss of Smell is a Key Symptom of CRSwNP

Loss of Smell is a Key Symptom of CRSwNP

interactivity
ADVENT on Air: OCS in CRSwNP Podcast

ADVENT on Air: OCS in CRSwNP Podcast

Podcast
The Compounded Burden of CRSwNP and Asthma

The Compounded Burden of CRSwNP and Asthma

interactivity
ADVENT On Air | Back Again: Predicting Recurrence in Chronic Rhinosinusitis with Nasal Polyps

ADVENT On Air | Back Again: Predicting Recurrence in Chronic Rhinosinusitis with Nasal Polyps

Podcast

Learning objectives

  • Recognize the key clinical features, complications, and overall burden of AFRS
  • Compare recurrence rates and disease impact of AFRS with CRSwNP, including pediatric considerations
Tags
CRSwNPBurden of Diseasetype 2 inflammationdisease severityPediatric
MAT-GLB-2603981 - 1.0 - 08/2026

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi | Regeneron Logo

© 2026 Sanofi and Regeneron Pharmaceuticals, Inc.

All rights reserved.
MAT-GLB-2302957 - 4.0 - 10/2025

All Rights Reserved.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: FinlandChange country/region